Medpace Holdings Class Action Reminder for Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 22 2026
0mins
Should l Buy MEDP?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that Medpace made false and misleading statements during the class period, concealing the true cancellation rates, which led investors to have overly optimistic growth expectations that could not sustain a 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of settlements in 2017, showcasing its strong capabilities in this field.
- How to Participate: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on joining the class action, with no upfront fees required, ensuring the protection of investors' rights.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MEDP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MEDP
Wall Street analysts forecast MEDP stock price to rise
7 Analyst Rating
1 Buy
4 Hold
2 Sell
Hold
Current: 415.270
Low
462.00
Averages
569.17
High
660.00
Current: 415.270
Low
462.00
Averages
569.17
High
660.00
About MEDP
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Medpace Holdings Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Medpace Faces Securities Class Action Lawsuit
- Significant Stock Drop: Medpace's stock plummeted by $84.30, a decline exceeding 15.9%, after revealing a Q4 2025 book-to-bill ratio of only 1.04x, significantly below the projected 1.15x, which directly undermines investor confidence and market performance.
- Discrepancy Between Internal Data and Public Statements: The lawsuit alleges that Medpace's leadership had access to internal data indicating high cancellation rates yet publicly portrayed a picture of robust business health, potentially leading to legal liabilities for misleading investors about the company's true financial condition.
- Fluctuating Cancellation Rates Raise Red Flags: Management described cancellation rates as
See More
Medpace Faces Class Action Lawsuit for Securities Fraud
- Class Action Filed: Bleichmar Fonti & Auld LLP has initiated a class action lawsuit against Medpace Holdings Inc. and its executives for securities fraud, reflecting significant investor concerns regarding the company's financial transparency after a substantial stock drop.
- Stock Price Plunge: Following the release of its financial results on February 9, 2026, Medpace reported a decline in its book-to-bill ratio to 1.04 due to increased cancellations, causing its stock price to plummet from $530.35 to $446.05, a drop of 15.9%, indicating a loss of market confidence in its financial health.
- Executive Departure: The resignation of Medpace's President, Jesse Geiger, after the stock decline adds to the uncertainty surrounding the company's future, potentially undermining investor trust and shareholder value.
- Legal Implications: Investors have until June 8, 2026, to apply to lead the case, and if the lawsuit succeeds, Medpace may face substantial damages that could impact its financial condition and future fundraising capabilities.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, indicating significant investor concern over the company's financial transparency.
- Financial Misconduct Allegations: The lawsuit alleges that Medpace and its executives violated the Securities Exchange Act of 1934 by overstating the projected book-to-bill ratio for Q4 2025, leading to investor misconceptions about the company's performance, which could undermine shareholder confidence and stock price.
- Stock Price Impact: Following the February 9, 2026 earnings report revealing a book-to-bill ratio of 1.04, significantly below expectations, Medpace's stock plummeted nearly 16%, reflecting market concerns about the company's growth potential and possibly prompting further legal actions from investors.
- Law Firm Credentials: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strength and influence in handling such cases, which may significantly impact Medpace's legal outlook.
See More
Reminder for Medpace Investors on Class Action Deadline
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that those who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) stock between April 22, 2025, and February 9, 2026, must file a lead plaintiff motion by June 8, 2026, to participate in the class action.
- Financial Miss: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the guidance of 1.15, primarily due to backlog cancellations reaching the highest level in over a year, resulting in a 15.9% drop in stock price the following day.
- False Statement Allegations: The lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts regarding the company's business and prospects, particularly regarding the overly optimistic projections of the book-to-bill ratio.
- Investor Losses: As a result of the defendants' misleading statements, investors suffered significant losses following the stock price decline, with the lawsuit aiming to seek compensation for affected investors, highlighting the company's responsibility for financial transparency and disclosure.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Medpace Holdings, Inc., seeking damages for investors who purchased securities between April 22, 2025, and February 9, 2026, highlighting significant investor dissatisfaction with the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace misrepresented its book-to-bill ratio as approximately 1.15 during earnings calls, despite contrary internal data, which could mislead investors and adversely affect the company's reputation.
- Investor Rights Protection: Affected investors have until June 5, 2026, to apply as lead plaintiffs, indicating a strong commitment to protecting investor rights and reflecting the regulatory scrutiny over securities markets.
- No-Risk Representation: Bronstein, Gewirtz & Grossman, LLC offers a no-risk representation model, charging fees only upon successful recovery, which lowers the barrier for investor participation and encourages more victims to join the lawsuit.
See More
Medpace Holdings Class Action Reminder for Investors
- Class Action Notice: Rosen Law Firm reminds investors who purchased Medpace Holdings (NASDAQ: MEDP) common stock between April 22, 2025, and February 9, 2026, to apply as lead plaintiffs by June 8, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants made false or misleading statements during the class period, concealing the true state of Medpace's backlog cancellation rate, which led investors to have overly optimistic growth expectations that could not sustain the projected 1.15 book-to-bill ratio.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its strong capabilities and successful track record in this field.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
See More
Medpace Faces Securities Class Action Lawsuit
- Significant Stock Drop: Medpace's stock plummeted by $84.30, a decline exceeding 15.9%, after revealing a Q4 2025 book-to-bill ratio of only 1.04x, significantly below the projected 1.15x, which directly undermines investor confidence and market performance.
- Discrepancy Between Internal Data and Public Statements: The lawsuit alleges that Medpace's leadership had access to internal data indicating high cancellation rates yet publicly portrayed a picture of robust business health, potentially leading to legal liabilities for misleading investors about the company's true financial condition.
- Fluctuating Cancellation Rates Raise Red Flags: Management described cancellation rates as
See More
Medpace Faces Class Action Lawsuit for Securities Fraud
- Class Action Filed: Bleichmar Fonti & Auld LLP has initiated a class action lawsuit against Medpace Holdings Inc. and its executives for securities fraud, reflecting significant investor concerns regarding the company's financial transparency after a substantial stock drop.
- Stock Price Plunge: Following the release of its financial results on February 9, 2026, Medpace reported a decline in its book-to-bill ratio to 1.04 due to increased cancellations, causing its stock price to plummet from $530.35 to $446.05, a drop of 15.9%, indicating a loss of market confidence in its financial health.
- Executive Departure: The resignation of Medpace's President, Jesse Geiger, after the stock decline adds to the uncertainty surrounding the company's future, potentially undermining investor trust and shareholder value.
- Legal Implications: Investors have until June 8, 2026, to apply to lead the case, and if the lawsuit succeeds, Medpace may face substantial damages that could impact its financial condition and future fundraising capabilities.
See More
Medpace Faces Class Action Lawsuit Allegations
- Class Action Initiation: Robbins Geller Rudman & Dowd LLP announces that investors who purchased Medpace Holdings Inc. (NASDAQ:MEDP) common stock between April 22, 2025, and February 9, 2026, can seek lead plaintiff status by June 8, 2026, indicating significant investor concern over the company's financial transparency.
- Financial Misconduct Allegations: The lawsuit alleges that Medpace and its executives violated the Securities Exchange Act of 1934 by overstating the projected book-to-bill ratio for Q4 2025, leading to investor misconceptions about the company's performance, which could undermine shareholder confidence and stock price.
- Stock Price Impact: Following the February 9, 2026 earnings report revealing a book-to-bill ratio of 1.04, significantly below expectations, Medpace's stock plummeted nearly 16%, reflecting market concerns about the company's growth potential and possibly prompting further legal actions from investors.
- Law Firm Credentials: Robbins Geller is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025, showcasing its strength and influence in handling such cases, which may significantly impact Medpace's legal outlook.
See More
Reminder for Medpace Investors on Class Action Deadline
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that those who purchased Medpace Holdings, Inc. (NASDAQ:MEDP) stock between April 22, 2025, and February 9, 2026, must file a lead plaintiff motion by June 8, 2026, to participate in the class action.
- Financial Miss: On February 9, 2026, Medpace reported a book-to-bill ratio of 1.04 for Q4 2025, significantly below the guidance of 1.15, primarily due to backlog cancellations reaching the highest level in over a year, resulting in a 15.9% drop in stock price the following day.
- False Statement Allegations: The lawsuit alleges that throughout the class period, defendants made materially false and misleading statements and failed to disclose adverse facts regarding the company's business and prospects, particularly regarding the overly optimistic projections of the book-to-bill ratio.
- Investor Losses: As a result of the defendants' misleading statements, investors suffered significant losses following the stock price decline, with the lawsuit aiming to seek compensation for affected investors, highlighting the company's responsibility for financial transparency and disclosure.
See More
Medpace Faces Class Action Lawsuit Over Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Medpace Holdings, Inc., seeking damages for investors who purchased securities between April 22, 2025, and February 9, 2026, highlighting significant investor dissatisfaction with the company's financial transparency.
- False Statement Allegations: The complaint alleges that Medpace misrepresented its book-to-bill ratio as approximately 1.15 during earnings calls, despite contrary internal data, which could mislead investors and adversely affect the company's reputation.
- Investor Rights Protection: Affected investors have until June 5, 2026, to apply as lead plaintiffs, indicating a strong commitment to protecting investor rights and reflecting the regulatory scrutiny over securities markets.
- No-Risk Representation: Bronstein, Gewirtz & Grossman, LLC offers a no-risk representation model, charging fees only upon successful recovery, which lowers the barrier for investor participation and encourages more victims to join the lawsuit.
See More
